[Treatment modification in multiple sclerosis: classifications, alternatives, and the outcomes].
Cendrowski
Wojciech
W
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D003131:Combined Modality Therapy / Q000379:methods; D004185:Disability Evaluation; D018450:Disease Progression; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods; D009103:Multiple Sclerosis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D009410:Nerve Degeneration / Q000209:etiology; D020078:Neurogenic Inflammation / Q000209:etiology; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D007166:Immunosuppressive Agents; D018696:Neuroprotective Agents